Skip to main content

Table 1 Baseline characteristics of patients in cohorts receiving and not receiving nutritional support meeting guideline standard

From: Impact of nutritional support that does and does not meet guideline standards on clinical outcome in surgical patients at nutritional risk: a prospective cohort study

  Calories or nutritional support not meeting guideline standards (n = 320) Calories and nutritional support meeting guideline standards (n = 205) P value
Male (percentage) 188 (58.7 %) 100 (48.8 %) 0.025
Age (mean ± SD) 66.43 ± 11.73 62.86 ± 13.99 0.006
Nutritional risk (mean ± SD) 4.09 ± 0.90 4.08 ± 0.93 0.134
BMI (mean ± SD) 21.09 ± 2.51 20.80 ± 2.56 0.687
Body weight loss >5 % 126 (39.4 %) 117 (57.1 %) <0.001
Food intake <75 % 240 (75.0 %) 142 (69.3 %) 0.150
Average calories (kcal/person/day) 15.35 ± 2.44 22.67 ± 1.48 < 0.001
Average N amount (g/person/day) 0.66 ± 0.51 1.15 ± 0.09 < 0.001
Duration of nutritional support (days) —— 10.5 ± 2.6 ——
Postoperative hospital stay (days) 15 (13,19) 15 (12, 20) 0.609
Diagnosisa (n)    < 0.001
A1 11 (3.4 %) 6 (2.9 %)  
A2 123 (38.4 %) 117 (57.1 %)  
B1 129 (40.3 %) 60 (29.3 %)  
B2 57 (17.8 %) 22 (10.7 %)  
  1. a A1 = benign gastrointestinal diseases: gastric ulcer, duodenal ulcer, gastric stromal tumours, jejunum stromal tumours, congenital megacolon, lengthy colon, rectal polyps, colonic diverticulitis; A2 = gastrointestinal cancer: gastric cancer, colon cancer, colorectal cancer, duodenal cancer, small intestine cancer, non-Hodgkin’s lymphoma; B1 = benign disease of the liver, bile ducts and pancreas: bile duct stones, bile duct stricture, Mirizzi syndrome, bile duct cyst, liver haemangioma, pancreas cystadenoma, papillary tumour of the pancreas, pancreatic pseudocyst; B2 = malignant cancer of the liver, bile ducts and pancreas: cholangiocarcinoma, gallbladder cancer, liver cancer, pancreatic cancer